PLD

DRUG17 trials

Sponsors

AGO Research GmbH, Genentech, Inc., Oncotherapeutics, AstraZeneca, Pfizer

Conditions

Adult Acute Lymphoblastic LeukemiaAdvanced MalignanciesAdvanced Solid TumorBladder CancerCholangiocarcinomaColorectal CancerEarly Breast CancerEpithelial Ovarian Cancer

Phase 1

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

CompletedNCT02206425

OncotherapeuticsMultiple Myeloma

Start: 2014-09-30End: 2018-03-06Updated: 2023-10-31

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Active, not recruitingNCT03872947

Toray Industries, IncBladder Cancer, Cholangiocarcinoma, Colorectal Cancer +9

Start: 2019-04-26End: 2026-06-30Updated: 2025-08-03

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

CompletedNCT03907969

AstraZenecaAdvanced Malignancies

Start: 2019-10-09End: 2022-12-07Updated: 2024-02-06

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

RecruitingNCT06687070

Ascentage Pharma Group Inc.Advanced Solid Tumor, Platinum-resistant Recurrent Ovarian Cancer

Start: 2024-12-17End: 2027-05-31Target: 50Updated: 2025-02-26

Phase 2

A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

TerminatedNCT01991210

Genentech, Inc.Ovarian Cancer

Start: 2014-02-06End: 2016-08-17Updated: 2017-08-21

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

TerminatedNCT02188368

OncotherapeuticsMultiple Myeloma

Start: 2014-07-07End: 2020-10-23Updated: 2023-11-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

CompletedNCT02272790

AstraZenecaOvarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Start: 2015-01-30End: 2023-03-08Updated: 2023-10-03

PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Poorly Differentiated Thyroid Carcinoma

Start: 2017-03-06End: 2019-12-31Target: 30Updated: 2018-01-03

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

RecruitingNCT05536102

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineGastric Cancer

Start: 2022-09-05End: 2027-09-30Target: 38Updated: 2023-03-09

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

RecruitingNCT06161025

Daiichi SankyoSolid Cancer

Start: 2024-02-27End: 2030-04-30Target: 860Updated: 2026-01-12

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

RecruitingNCT06787612

Regeneron PharmaceuticalsFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2025-05-28End: 2028-10-30Target: 220Updated: 2026-04-02

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Active, not recruitingNCT07109414

Novita Pharmaceuticals, Inc.Platinum-resistant Ovarian Cancer

Start: 2025-12-29End: 2029-10-24Target: 380Updated: 2026-03-09

Phase 3

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

CompletedNCT01837251

AGO Research GmbHRecurrent Platinum-sensitive Ovarian Cancer

Start: 2013-05-31End: 2021-01-31Updated: 2021-07-13

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

CompletedNCT02580058

PfizerOvarian Cancer

Start: 2015-12-21End: 2022-07-12Updated: 2023-07-10

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

TerminatedNCT03690739

AGO Research GmbHRecurrent Ovarian Carcinoma

Start: 2019-08-09End: 2021-03-03Updated: 2022-02-24

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Fudan UniversityEarly Breast Cancer

Start: 2017-09-01End: 2020-10-31Target: 272Updated: 2019-05-14

Unknown Phase

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Adult Acute Lymphoblastic Leukemia

Start: 2013-10-10End: 2019-06-30Target: 40Updated: 2018-02-05

Related Papers

Abstract 1820: Pharmacokinetic-tumor growth inhibition modeling of raludotatug deruxtecan (R-DXd) to support phase 3 dose selection in platinum-resistant ovarian cancer (PROC).

Cancer Research2026-04-03

Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial

The Oncologist2025-06-011 citations

REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors.

Journal of Clinical Oncology2025-05-28

The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study

British Journal of Cancer2025-05-176 citations

Development and validation of an antidrug antibody assay for TRK-950 using Melon™ gel and SPEAD pretreatment.

2025-04-17

Pharmacokinetic-pharmacodynamic analysis of myelosuppression with raludotatug deruxtecan (R-DXd) in patients with advanced solid tumors

2025-02-18

REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).

Journal of Clinical Oncology2024-06-017 citations

A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Journal of Clinical Oncology2024-06-012 citations

A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Journal of Clinical Oncology2024-01-201 citations

Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both

The Oncologist2023-09-041 citations

Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.

Journal of Clinical Oncology2023-06-011 citations

Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950

Cancer Research Communications2023-04-1815 citations

Abstract 3923: Identification of membrane-expressed CAPRIN-1 as a novel and universal cancer target and generation of a therapeutic anti-CAPRIN-1 antibody TRK-950

Cancer Research2023-04-04

A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.

Journal of Clinical Oncology2023-01-242 citations

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

2021-06-15274 citations

Abstract CT248: AZD7648: A Phase I/IIa first-in-human trial of a novel, potent and selective DNA-PK inhibitor in patients with advanced malignancies

Cancer Research2020-08-158 citations

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

2020-04-16113 citations

The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-<i>a</i>]pyridin-6-yl)amino]-9-(tetrahydro-2<i>H</i>-pyran-4-yl)-7,9-dihydro-8<i>H</i>-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor

Journal of Medicinal Chemistry2019-12-1876 citations

Carboplatin/Caelyx/Bevacizumab vs. Carboplatin/Gemcitabine/Bevacizumab beim platinsensiblen Ovarialkarzinomrezidiv: Ergebnisse der prospektiv-randomisierten Phase III AGO-OVAR 2.21 Studie

Geburtshilfe und Frauenheilkunde2019-08-01

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Journal of Clinical Oncology2019-05-2022 citations

8 more papers not shown